Acquisition History Truvic was acquired by Imperative Care in 2021 and has two FDA-cleared thrombectomy systems, indicating a possible opportunity to align sales with Imperative Care’s broader product ecosystem and leverage cross-sell of complementary devices or integrated solutions.

Patent Tension Recent patent infringement litigation involving Truvic suggests a potential need for legal-risk mitigation services, IP management tools, and due diligence support for partners and customers evaluating collaboration or procurement of Truvic technologies.

Product Focus With an emphasis on peripheral thrombus treatment and thrombectomy tools, there is an opportunity to pitch safety, regulatory, and quality assurance solutions, as well as post-market surveillance and reporting capabilities tailored to interventional devices.

Financial Signals Low reported revenue range combined with small to mid-size employee base signals a potential for cost-effective, scalable tech or services (cloud, analytics, compliance, training) to support a lean operations model and accelerate market adoption.

Tech Stack Fit Utilizing cloud and analytics platforms (AWS, Salesforce, Minitab, HTTP/3) presents a path to offer integration, data analytics, and cloud-based training or telemetry solutions that enhance device performance monitoring and customer success.